Physician profile
David E Feinstein
NPI 1477568707
$455.00
in general payments reported to CMS, 2019-2025
14 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.75 · 2020: $11.18 · 2021: $25.15 · 2022: $40.14 · 2024: $78.87 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $70.37 | 2021-2025 | |
| Abbvie INC. | $55.37 | 2024-2025 | |
| Genentech USA, INC. | $53.84 | 2019-2020 | |
| Organon LLC | $47.62 | 2024-2025 | Hadlima, Renflexis |
| Amgen INC. | $34.25 | 2025 | Uplizna, Evenity, Prolia |
| Janssen Biotech, INC. | $33.13 | 2022-2025 | Tremfya |
| Ucb, INC. | $31.17 | 2024-2025 | Bimzelx |
| Aurinia Pharma U.S., INC. | $28.41 | 2025 | Lupkynis |
| Pharming Healthcare, INC. | $26.00 | 2022 | |
| Lilly USA, LLC | $17.34 | 2024 | Taltz |
| Radius Health, INC. | $16.45 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $14.09 | 2019 | |
| Pfizer INC. | $13.78 | 2021 | |
| Glaxosmithkline, LLC. | $13.18 | 2024 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Feinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.